Creative Commons source reading · Multiple sclerosis and neuroimmunology
MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder.
Giordani Rodrigues Dos Passos; Luana Michelli Oliveira; Bruna Klein da Costa; Samira Luisa Apostolos-Pereira; Dagoberto Callegaro; Kazuo Fujihara; Douglas Kazutoshi Sato
Originally published in Frontiers in neurology · 2018-04-04
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) have been found in some cases diagnosed as seronegative neuromyelitis optica spectrum disorder (NMOSD). MOG-IgG allowed the identification of a subgroup with a clinical course distinct from that of NMOSD patients who are seropositive for aquaporin-4-IgG antibodies. MOG-IgG is associated with a wider clinical phenotype, not limited to NMOSD, with the majority of cases presenting with optic neuritis (ON), encephalitis with brain demyelinating lesions, and/or myelitis. Therefore, we propose the term MOG-IgG-associated Optic Neuritis, Encephalitis, and Myelitis (MONEM). Depending on the clinical characteristics, these patients may currently be diagnosed with NMOSD, acute disseminated encephalomyelitis, pediatric multiple sclerosis, transverse myelitis, or ON. With specific cell-based assays, MOG-IgG is emerging as a potential biomarker of inflammatory disorders of the central nervous system. We review the growing body of evidence on MONEM, focusing on its clinical aspects.
Conclusion
Despite some overlap, MONEM exhibits different pathophysiological and phenotypic features than both AQP4-IgG-associated NMOSD and typical MS. In addition, the clinical spectrum of MONEM expands beyond NMOSD, likely including ADEM and other demyelinating syndromes. We believe that MOG-IgG and AQP4-IgG should be considered biomarkers of different disease processes instead of different biomarkers for the same condition. It is possible that MOG-IgG-associated “NMOSD” is not truly a part of the NMO spectrum; instead, MONEM could represent another disorder that may overlap in certain clinical phenotypes.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
